Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of CXCL1 and CXCL1 with SX-682 on gene expression for human epidermal melanocytes (NHEM) cells.

ABSTRACT: Effect of CXCL1 and CXCL1 with SX-682 on gene expression for human epidermal melanocytes (NHEM) cells.

PROVIDER: PRJNA925525 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23130200_1.fastq.gz	Fastqsanger.gz
	SRR23130200_2.fastq.gz	Fastqsanger.gz
	SRR23130201_1.fastq.gz	Fastqsanger.gz
	SRR23130201_2.fastq.gz	Fastqsanger.gz
	SRR23130202_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Effect of CXCL1 and CXCL1 with SX-682 on gene expression for human epidermal melanocytes (NHEM) cells.

Project description:To gain insight into how CXCL1 activation of CXCR2 regulates the expression of stemness and differentiation markers, RNAseq analysis was performed on normal human epidermal melanocyte (NHEM) cultures treated with CXCL1 or with CXCL1 and SX-682.

2023-06-07 | GSE223285 | GEO

Effect of SX-682 on gene expression for BrafV600E/PTEN-/- mice.

Project description:To evaluate the effect of the dual CXCR1/CXCR2 inhibitor SX-682 on tumor growth, BrafV600E/PTEN-/- mice were fed with either SX-682 chow (0.756 g/kg of SX-682, Syntrix Pharmaceuticals, Inc) or control chow for RNA-seq analysis.

2023-06-07 | GSE223286 | GEO

Effect of SX-682 treatment on gene expressions of three murine cell lines.

Project description:To identify tumor-specific transcriptional changes following SX-682 treatment, we performed RNA sequencing on each of the MelanA, B16F0, and B16F10 cell lines.

2023-06-07 | GSE223288 | GEO

ChIPseq analysis of changes in binding of TFCP2L1 antibody in B16F0 cells in response to SX-682 treatment.

Project description:To define the activity of TFCP2L1 following CXCR2 perturbation, we performed chromatin immunoprecipitation and sequencing analysis (CHIPseq) on B16F0 tumorigenic melanoma cells following treatment with vehicle or SX-682.

2023-06-07 | GSE223289 | GEO

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

Project description:This phase Ib/II trial studies the side effects and best dose of SX-682 that can be given alone and in combination with nivolumab in treating patients with RAS-Mutated, microsatellite stable (MSS) colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). SX-682 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 alone and together with nivolumab may kill more tumor cells.

| 2355422 | ecrin-mdr-crc

Effect of SX-682 on gene expression for BrafV600E/PTEN-/- mice.

Project description:Effect of SX-682 on gene expression for BrafV600E/PTEN-/- mice.

| PRJNA925526 | ENA

Effect of SX-682 treatment on gene expressions of three murine cell lines.

Project description:Effect of SX-682 treatment on gene expressions of three murine cell lines.

| PRJNA925528 | ENA

Gene expression patterns in Normal Human Epidermal Melanocytes at different time points

Project description:Normal human epidermal melanocytes (NHEM, purchased from PromoCell) were culture for one (7 days) or two weeks (14 days) and subsequently, total RNA was isolated and cDNA array analysis was performed. The array was used to determine general gene expression patterns in primary melanocytes. Moreover, gene expression alterations during cell culturing (one or two weeks) can be detected. Finally, the gene expression array is used to compared gene expression paterns with melanoma cell and tissue gene expression patterns or with other primary cell lines.

2020-11-16 | GSE108969 | GEO

MiRNA-sequencing in normal human epidermal melanocytes, melanoblast-related cells and melanoma cell lines

Project description:The study aims to identify differences in miRNA expression during melanoma development. Therefore, normal human epidermal melanocytes (NHEM) were de-differentiated into melanoblast-related cells (MBrCs) to model processes during embryonic differentiation and to compare them to the tumorigenic phenotype in melanoma development.

2021-05-26 | GSE174334 | GEO

Glycomic gene comparison between human epidermal melanocytes and human metastatic melanoma cells

Project description:To discover potential biomarkers of melanoma development and progression, we embarked on studies comparing the glycomic gene profiles of normal human epidermal melanocytes with human metastatic melanoma (MM) cells represented by A375 and G361 cell lines. Glycomic features embody all of those enzymatic, membranous and regulatory proteins that influence glycan ‘sugar’ formation/degradation on a cell. Comparative expression profiling of glycomic genes indicated that several genes were differentially expressed between normal melanocytes and MM cells. We speculate that glycome genes differentially expressed in MM cells help drive malignant and metastatic behavior of MM cells and could potentially serve as a biomarker(s) of melanoma progression.

2017-08-13 | GSE94837 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data